There is an item that Rep. Choi Jae-hyung of the People's Power, who has been criticized by the pharmaceutical industry for insisting on lowering generic drug prices during the parliamentary audit, is praising his salary registration. It is the super antibiotic Zerbaxa. At the HIRA parliamentary audit held on the 13th, he said, "200 to 300 people die every year from antibiotic resistance, and Zerbaxa's benefit was a meaningful decision." He also argued that generic drug prices should be lowered to secure health insurance finances, saying that it is necessary to make a forward-looking decision to set the price of such super antibiotics. Zerbaxa is an antimicrobial agent used to treat complex intra-abdominal infections,